Baxalta Innovations

Company snapshot

Shire acquired Baxalta on June 3, 2016. Following this date, this page will no longer be actively monitored. There will be no updates or responses posted on this page. For continued news and updates, we encourage you to follow Shire on LinkedIn at https://www.linkedin.com/company/shire

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Baxalta Innovations. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Baxalta Innovations.

1. Jun 8, 2026 Clinical update

   090701 — Phase 3

2. Jun 8, 2026 Clinical update

   TAK-755-3002 — Phase 3

3. Jun 8, 2026 Clinical update

   071102 — Phase 3

4. Jun 8, 2026 Clinical update

   Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method — Phase 3

5. May 26, 2026 Clinical update

   BAX855 — Phase 3

View all clinical trial activity →

• What is Baxalta Innovations?

  Baxalta is a pharma organization headquartered in Illinois, USA. Primary therapeutic focus areas include Hemophilia A, Hemophilia A or B With Inhibitors, Congenital Thrombotic thrombocytopenic purpura (cTTP), Hereditary severe von Willebrand Disease in children, Primary Immunodef

• Is Baxalta Innovations publicly traded?

  Baxalta Innovations appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Baxalta Innovations develop or market?

  We link 12 drug profile(s) where Baxalta Innovations is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/baxalta-innovations-gmbh#company-drugs.

• What are the latest developments for Baxalta Innovations?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Baxalta Innovations focus on?

  Baxalta Innovations focuses on Hemophilia A, Hemophilia A or B With Inhibitors, Congenital Thrombotic thrombocytopenic purpura (cTTP) based on our analysis of their pipeline programs and drug development activities.